The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
|Videos|July 16, 2014
Updates In CLL Treatments
Author(s)John C. Byrd, MD
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses updates in the treatment of CLL.
Advertisement
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses updates in the treatment of CLL.
Clinical Pearls:
- Patient-friendly therapies are changing the lives of patients with CLL.
- These oral therapies are active and successfully controlling the disease for an extended period of time.
- By combining new, active agents, physicians are moving closer to finding a cure for patients with CLL.
- With updates in treatment options, physicians can now start to move away from using chemotherapy to treat patients with CLL.
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The FDA granted orphan drug designation to Cardiff Oncology’s PLK1 inhibitor onvansertib for relapsed or refractory CMML after early phase 1 activity.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5